About Genesys
Expertise. Experience. Insight.
Genesys Capital invests in and builds companies in the high-growth sectors of biotechnology, pharmaceuticals and medical technology. We have a proven track record of identifying emerging bioscience opportunities, and transforming them into commercially successful companies. That track record is fuelled by robust industry relationships, broad business expertise, and a deep understanding of the life sciences sector.

Genesys has generated more than 18 exits from 38 portfolio companies and has invested more than $250M. Our third institutional fund is closed and we’re actively considering new, high-potential life science companies for investment.
Why Genesys succeeds
Robust industry relationships, deep subject area knowledge, and proven insights let us identify viable companies early… and arm them to perform.
Stable and proven team
Our team has worked together for two decades of successful and continuous partnership.

Robust industry relationships
Long standing relationships with leading North American research institutes and universities provide us with early insights into top-tier research discoveries and world-class innovation, as well as preferential access to high potential deal flow and deep diligence expertise.

Proven strategy and profitable returns
We use our local world class research corridor as a lens to identify the most promising investment opportunities and apply our company creation strategy – a formula that has repeatedly proven its effectiveness with profitable returns.

Essential expertise for scale
We provide the critical expertise portfolio companies need to scale from great science on the bench to viable commercial enterprises competing in the global market. From thought leaders to executives to key advisors, our network and inhouse expertise give our companies the tools they need to perform.